TAM KALINLIKTA NASAL ALAR DEFEKTİN KOMPOZİT KULAK GREFTİ ve HİPERBARİK OKSİJEN TEDAVİSİ İLE ONARIMI

Abstract

Nasal alar bölge defektlerinin estetik ve fonksiyonel açıdan onarımının yapılması cerrah için oldukça zordur. Literatürde değişik teknikler tarif edilmiş olsada, ideal onarım tekniği mevcut değildir. Biz kompozit kulak grefti ile hiperbarik oksijen tedavisini kombine olarak 21 yaşındaki erkek hastadaki nasal alar defekti için kullandık. Kompozit kulak grefti hiperbarik oksijen tedavisi ile kombine edilerek tam kalınlıktak nasal alar defektlerin onarımında kullanıldığında iyi fonksiyonel ve estetik sonuç sağlanabilir.

Keywords

• Nasal Alar Defekt, Kompozit Greft, Hiperbarik Oksijen

References

1. 1. Svedman P. Advancement flaps for alar reconstruction. Ann Plast Surg 1990;25(6):502-7.
2. 2. Burget GC, Menick FJ. The subunit principle in nasal reconstruction. Plast Reconstr Surg 1985;76(2):239-47.
3. 3. Keck T, Lindemann J, Kuhnemann S, et al. Healing of composite chondrocutaneous auricular grafts covered by skin flaps in nasal reconstructive surgery. Laryngoscope 2003;113(2):248-53.
4. 4. Lewis D, Goldztein H, Deschler D. Use of hyperbaric oxygen to enhance auricular composite graft survival in the rabbit model. Arch Facial Plast Surg 2006;8(5):310- 13.
5. : 165-176.
6. Koch AE, Harlow LA, Haines GK, et al. Vascular
7. endothelial growth factor. A cytokine modulating
8. endothelial function in reumatoid arthritis, J Immunol

9. ; 152 (8): 4149-4156.
10. Miller JW, Adamis AP, Aiello LP. Vascular
11. endothelial growth factor in ocular neovascularization
12. and proliferative diabetic retinopathy. Diabetes Metab
13. Rev 1997; 13; 37-50.
14. Saaristo A, Karpanen T, Alitalo K. Mechanisms of
15. angiogenesis and their use in the ınhibition of tumor
16. growth and metastasis. Oncogene 2000; 19: 6122-
17. -
18. Davis S, Aldrich TH, Jones PF, Acheson A, Compton
19. DL, Jain V, et al. Isolation of angiopoietin-1, a ligand
20. for the tie2 receptor, by secretion-trap expression
21. cloning. Cell 1996; 87 (7): 1161-1169.
22. Maisonpierre PC, Suri C, Jones PF, et al.
23. Angiopoietin-2, a natural antagonist for Tie2 that
24. disrupts in vivo angiogenesis. Science 1997; 277
25. (5322): 55-60.
26. Konac E, Onen HI, Metindir J, Alp E, Biri AA,
27. Ekmekci A. Lack of association between -460 C/T
28. and 936 C/T of the vascular endothelial growth factor
29. and angiopoietin-2 exon 4 G/A polymorphisms and
30. ovarian, cervical, and endometrial cancers. DNA Cell
31. Biol 2007; 26: 453-463.
32. Onen IH, Konac E, Eroglu M, Guneri C, Biri H,
33. Ekmekci A. No association between polymorphism in
34. the vascular endothelial growth factor gene at
35. position-460 and sporadic prostate cancer in the
36. Turkish population. Mol Biol Rep 2008; 1: 17-22.
37. Wang GL, Semenza GL. Purification and
38. characterization of hypoxia-inducible factor 1. J Biol
39. Chem 1995; 270: 1230–1237.
40. Konac E, Onen HI, Metindir J, Alp E, Biri AA,
41. Ekmekci A. An investigation of relationships between
42. hypoxia-inducible factor-1 alpha gene polymorphisms
43. and ovarian, cervical and endometrial cancers. Cancer
44. Detect Prev 2007; 31: 102-109.
45. Vogelstein B, Kinzler KW. Cancer genes and the
46. pathways they control. Nat Med 2004; 10: 789–799.
47. Hartsough MT, Steeg PS. Nm23/nucleoside
48. diphosphate kinase in human cancers. J Bioenerg
49. Biomembr 2000; 32 (3): 301-308.
50. Fearon ER. Human cancer syndromes: clues to the
51. origin and nature of cancer. Science 1997; 278: 1043-
52. -
53. Ghilardi G, Biondi ML, Caputo M, et al. A single
54. nucleotide polymorphism in the matrix
55. metalloproteinase-3 promoter enhances breast cancer
56. -
57. Marmara Medical Journal 2008;21(3);282-295
58. Abdullah Ekmekçi ve Ark.
59. Gen polimorfizmi ve kansere yatkınlık
60. susceptibility. Clinical Cancer Res 2002; 8 (12):
61. -3823.
62. Ghilardi G, Biondi ML, Erario M, Guagnellini E,
63. Scorza R. Colorectal carcinoma susceptibility and
64. metastases are associated with matrix
65. metalloproteinase-7 promoter polymorphisms. Clinic
66. Chem 2003; 49: 1940-1942.
67. Eroglu A, Ulu A, Cam R, Akar N. Plasminogen
68. activator inhibitor-1 gene 4G/5G polymorphism in
69. patients with breast cancer. J BUON 2006; 11: 481-
70. -
71. Lei H, Hemminki K, Johansson R, Altieri A, Enquist
72. K, Henriksson R, et al. PAI-1 -675 4G/5G
73. polymorphism as a prognostic biomarker in breast
74. cancer, Breast Cancer Res Treat, DOI:
75. 1007/s10549-007-9635-3 July 7; 2007.
76. van den Bemd GJ, Pols HA, van Leeuwen JP. Antitumor
77. effects of 1,25-dihydroxyvitamin D3 and
78. vitamin D analogs. Curr Pharm Des 2000; 6: 717-732.
79. Haussler MR, Whitfield GK, Haussler CA. The
80. nuclear vitamin D receptor: biological and molecular
81. regulatory properties revealed. J Bone Miner Res
82. ; 1: 325– 349.
83. Drocourt L, Ourlin JC, Pascussi JM, Maurel P,
84. Vilarem MJ. Expression of CYP3A4, CYP2B6, and
85. CYP2C9 is regulated by the vitamin D receptor
86. pathway in primary human hepatocytes. J Biol Chem
87. ; 277: 25125–25132.
88. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J
89. Physiol Renal Physiol 1999; 277: F157–175.
90. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA,
91. Van Leeuwen JP. Genetics and biology of vitamin D
92. receptor polymorphisms. Gene 2004; 338: 143–156.
93. Obara W, Suzuki Y, Kato K, Tanji S, Konda R,
94. Fujioka T. Vitamin D receptor gene polymorphisms
95. are associated with increased risk and progression of
96. renal cell carcinoma in a Japanese population. Int J
97. Urol 2007; 14: 483-487.
98. Taylor JA, Hirvonen A, Watson M, Pittman G,
99. Mohler JL, Bell DA. Association of prostate cancer
100. with vitamin D receptor gene polymorphism. Cancer
101. Res 1996; 56: 4108-4110.
102. Kadiyska T, Yakulov T, Kaneva R, Nedin D,
103. Alexandrova A, Gegova A, et al. Vitamin D and
104. estrogen receptor gene polymorphisms and the risk of
105. colorectal cancer in Bulgaria. Int J Colorectal Dis
106. ; 22 (4): 395-400.
107. Lundin AC, Söderkvist P, Eriksson B, BergmanJungeström
108. M, Wingren S. Association of breast
109. cancer progression with a vitamin D receptor gene
110. polymorphism. South-East Sweden Breast Cancer
111. Group. Cancer Res 1999; 59: 2332-2334.
112. Oakley-Girvan I, Feldman D, Eccleshall TR,
113. Gallagher RP, Wu AH, Kolonel LN, et al. Risk of
114. early-onset prostate cancer in relation to germ line
115. polymorphisms of the vitamin D receptor. Cancer
116. Epidemiol Biomarkers Prev 2004; 13 (8): 1325-1330.
117. Morrison NA, Yeoman R, Kelly PJ, Eisman JA.
118. Contribution of trans-acting factor alleles to normal
119. physiological variability: vitamin D receptor gene
120. polymorphism and circulating osteocalcin. Proc Natl
121. Acad Sci USA 1992; 89: 6665-6669.
122. Faraco JH, Morrison NA, Baker A, Shine J, Frossard
123. PM. ApaI dimorphism at the human vitamin D
124. receptor gene locus. Nucleic Acids Res 1989; 17:
125. -
126. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L,
127. Nguyen TV, et al. Prediction of bone density from
128. vitamin D receptor alleles. Nature 1994; 367 (6460):
129. -287.
130. Onen HI, Ekmekci A, Eroğlu M, Konac E, Yeşil S,
131. Biri H: Association of genetic polymorphisms in
132. vitamin D receptor gene and susceptibility to sporadic
133. prostate cancer. Exp Biol Med 2008; 233 (12): In
134. Press.